ATRC-101 is under clinical development by Atreca and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ATRC-101’s likelihood of approval (LoA) and phase transition for Esophageal Squamous Cell Carcinoma (ESCC) took place on 31 May 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ATRC-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ATRC-101 overview

ATRC-101 is under development for the treatment of solid tumors including non-small cell lung adenocarcinoma, acral melanoma, colorectal cancer, epithelial ovarian cancer, hepatocellular carcinoma, triple negative breast cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma (ESCC), transitional cell carcinoma (urothelial cell carcinoma) and breast adenocarcinoma. It is administered as intravenous infusion. The drug candidate is an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody developed through driver antigen engagement program based on immune repertoire capture (IRC) technology. ATRC-101 targets ribonucleoprotein (RNP) complex, it binds to a polyadenylate-binding protein (PABP-1) within its target RNP complex.

Atreca overview

Atreca is a biotechnology company. It develops novel therapies based on the human immune response. The company develops proprietary immune repertoire capture technology that act as an engine for the discovery and development of antibody based therapeutics, diagnostics, vaccines and research reagents. Its technology has partnerships with pharmaceutical companies, academic institutions, non-profit foundations and governmental entities. Its pipeline products are intended for the treatment of breast tumor, lung tumor, colon tumor and other solid tumors. Atreca is headquartered in Redwood City, California, the US.

Quick View ATRC-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • ATRC-101
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.